Medtronic-Sponsored Study Finds Pacemakers Reduce Fainting in Patients
Medtronic, Inc. announces the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered from fainting due to neurocardiogenic syncope had fewer fainting occurrences when treated with a Medtronic pacemaker. The results, which found a statistically and clinically significant 57 percent relative reduction of fainting recurrence in patients at two years, were presented in a late-breaking clinical trial session at the American College of Cardiology’s (ACC’s) 61st Annual Scientific Session in Chicago. In the study, patients at high risk for syncope recurrence (known as asystolic neurally-mediated syncope or NMS) were identified through the use of Medtronic’s Reveal® family of Insertable Cardiac Monitors (ICM), thereby allowing physicians to determine which patients could benefit from a pacemaker implant. Learn more at http://bit.ly/Hkhf5a.